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Background: Use of the chemotherapeutic drug doxorubicin (DOX) is associated with serious cardiotoxicity, as it
increases levels of reactive oxygen species (ROS). N-3 polyunsaturated fatty acid dietary supplements can be of
benefit to patients undergoing cancer therapy. The aims of this study were to determine whether DOX-induced
cardiotoxicity is related to mitochondrial uncoupling proteins and whether eicosapentaenoic acid (EPA, C20:5 n-3)
or docosahexaenoic acid (DHA, C22:6 n-3) affects DOX-induced cardiomyocyte toxicity.
Results: Treatment of H9C2 cells with DOX resulted in decreased cell viability and UCP2 expression. Treatment with
100 μM EPA or 50 μM DHA for 24 h resulted in a maximal mitochondria concentration of these fatty acids and
increased UCP2 expression. Pretreatment with 100 μM EPA or 50 μM DHA prevented the DOX-induced decrease in
UCP2 mRNA and protein levels, but these effects were not seen with EPA or DHA and DOX cotreatment. In addition,
the DOX-induced increase in ROS production and subsequent mitochondrial membrane potential change (Δψ) were
significantly attenuated by pretreatment with EPA or DHA.
Conclusion: EPA or DHA pre-treatment inhibits the DOX-induced decrease in UCP2 expression, increase in ROS
production, and subsequent mitochondrial membrane potential change that contribute to the cardiotoxicity of DOX.
Keywords: EPA, DHA, Doxorubicin, ROS, UCP2Background
The anthracycline antibiotic doxorubicin (DOX) is one
of the most highly prescribed chemotherapeutic drugs
for the treatment of a variety of human cancers [1]. Un-
fortunately, in addition to its potent antitumor effect,
DOX use is associated with a number of unwanted side
effects, especially serious cardiac toxicity, and this com-
plication represents a major obstacle to the prolonged
use of the drug [2]. DOX cardiotoxicity seems to be a
multi-factorial process that leads to cardiomyocyte death
as the terminal downstream event. DOX exerts its anti-
cancer and cardiotoxic actions by different mechanisms,
the anticancer response being associated with DNA* Correspondence: ronichen@ntu.edu.tw
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unless otherwise stated.intercalation, topoisomerase-II inhibition, and apoptosis,
and the cardiotoxicity being mainly ascribed to oxidative
stress [3,4]. The role of oxidative stress in DOX-induced
cardiotoxicity is supported by the fact that cardiotoxicity
is reduced in animals by treatment with a variety of anti-
oxidants [5,6]. In addition, DOX causes mitochondrial
dysfunction in the heart by modulating the mitochondrial
membrane lipid content, interacting with cardiolipin, inhi-
biting the activity of several mitochondrial proteins, and
displacing α-enolase from mitochondria [7,8]. A recent
study indicated that DOX induces cardiotoxicity mainly
by disrupting the catalytic cycle of topoisomerase 2β
(Top2β) [4]. Through this disruption of Top2β function,
DOX causes DNA double-strand breaks and changes in
the transcriptome [4], which contributes to the gener-
ation of reactive oxygen species (ROS) and to the mito-
chondrial dysfunctions, thus resulting in apoptosis.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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onstrated the beneficial effects of n-3 poly-unsaturated fatty
acids (PUFAs) in cardiovascular disease [9,10]. The results
from such studies justify n-3 PUFA supplementation in the
primary and secondary prevention of several clinical con-
ditions, including coronary heart disease, sudden cardiac
death, and heart failure [9,10]. Consumption of n-3 PUFAs
in fish oil, specifically eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), decreases the risk of heart
failure and attenuates pathological cardiac remodeling in
response to pressure overload. Dietary supplementation
with EPA and DHA can also affect cardiac mitochondrial
function and energetics through the alteration of mem-
brane phospholipids [11]. In addition, the benefits of fish
oil dietary supplements given before or during cancer
therapy include increasing the anticancer drug efficacy
[12-14] and reducing the cardiac side effects of various
chemotherapeutic treatments [15,16].
The mitochondrial uncoupling proteins UCP2 and
UCP3 have been shown to be important in the fields of
thermogenesis, obesity, diabetes, free radical biology, and
heart failure [17]. When activated by superoxide, ROS, or
alkenals, UCPs increase mitochondrial proton conductance
to cause mild uncoupling and so decrease mitochondrial
superoxide production, and are thus providing protection
against oxidative damage [17]. Nedergaard and Cannon
[18] reported that UCP mRNA levels are increased in the
presence of long-chain free fatty acids. In addition to
regulating the mitochondrial superoxide production,
UCP overexpression protects against oxidative stress-
induced apoptosis [19].
Previous studies have shown that fish oil dietary sup-
plements are of benefit to patients undergoing cancer
therapy [15,16,20]; however, it is still unclear whether
EPA or DHA has a beneficial effect on DOX therapy, es-
pecially in terms of reducing its cardiotoxicity. Moreover,
there have not been any studies on a possible association
between DOX cardiotoxicity and UCP2 function. The aim
of this study was to determine whether DOX-induced
toxicity is related to UCP2 levels and to investigate
whether EPA or DHA affects DOX-induced cardiomyo-
cyte toxicity.
Methods
Cell culture and treatment
Cardiomyoblast H9C2 was obtained from the American
Type Culture Collection (ATCC) and cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco
BRL, Grand Island, NY. USA) containing 10% fetal bovine
serum (FBS, Hyclone, Auckland, NZ), 2 mM L-glutamine,
0.1 mM non-essential amino acids (Gibco BRL, Grand
Island, NY, USA), 100 units/ml of penicillin, and 100 μg/
ml of streptomycin (Gibco BRL, Grand Island, NY, USA)
at 37°C in a humidified chamber with 5% CO2. After thesubcultured cells had been incubated for 24 h and become
attached to the plate, various concentrations of EPA or
DHA (Sigma-Aldrich, St. Louis, MO, USA) were added in
serum-free DMEM containing 0.1% bovine serum albu-
min (BSA) (Sigma-Aldrich, St. Louis, MO, USA) for 24 or
48 h to investigate the incorporation of n-PUFAs into sub-
cellular fractions. In addition, H9C2 cells with or without
pretreatment for 24 h with EPA or DHA in DMEM con-
taining 0.1% BSA were left untreated or were treated
with 1 μM DOX in DMEM containing 10% FBS for
24 h, then were harvested for analysis, while other cells
were cotreated for 24 h with EPA or DHA plus DOX in
DMEM containing 10% FBS.
After DOX treatment, the cells were incubated for 2 h
with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide; Sigma-Aldrich, St. Louis, MO, USA),
then the absorbance of the sample at 450 nm was mea-
sured using a microplater reader. Experiments were re-
peated three times.
Subcellular fractionation
All steps were performed at 4°C. The cells were lysed
with 250 mM sucrose, 20 mM HEPES, 10 mM KCl,
1.5 mM MgCl2, 1 mM EDTA, and 1 mM EGTA and the
lysate passed through a 25G needle 10 times and left for
20 min, then centrifuged at 720 g for 5 min to obtain
the nuclear pellet. The supernatant was removed and
centrifuged at 10,000 g for 20 min to obtain the mito-
chondria fraction, then the supernatant was centrifuged
at 100,000 g for 60 min to obtain the membrane and
cytosol fractions [21].
Determination of fatty acid composition
To determine the fatty acid composition, lipids were ex-
tracted from the total cell lysate or mitochondria. Each
sample plus 50 μg of 1,2-dinonadecanoyl-sn-glycero-3
phosphocholine (C19:0 PC; Avanti Polar Lipids Inc.;
Alabaster, Alabama), as an internal standard was homoge-
nized in a 2/1/0.75 (v/v) mixture of methanol/chloroform/
water and centrifuged at 1200 g for 30 min at 16°C and
the upper phase discarded. The lower phase was dried
under nitrogen and resuspended in 14% borontrifluor-
ide methanol (Merck Schuchardt OHG, Hohenbrunn,
Germany) followed by heating at 90°C for 40 min. After
cooling, the free fatty acids were extracted with an 8/3
(v/v) mixture of pentane/water by vortexing and the or-
ganic phase recovered and dried under nitrogen. The
extracts was resuspended in 50 μl of heptane for gas
chromatography analysis on a capillary column (DB-23
60 m × 0.25 mm × 0.25 μm, Agilent J&W, USA). The gas
chromatograph was an Agilent 7890 series GC equipped
with a flame ionization detector (FID/EPC G3440A) and
an autoinjector module. The oven temperature was held
at 120°C for 2 min, then was increased at 8°C per min to
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3°C per min to 240°C and held at 240°C for 2 min. The in-
jector and detector were both at 240°C and the flow rate
of carrier gas, helium, air and nitrogen was 40 ml/min,
450 ml/min, and 25 ml/min, respectively. Components
were identified by comparison of the retention time with
those of authentic standards (Supelco 37 Comp. Fame
Mix™, Supelco Inc. Belletonte PA) [22].
Quantitative real-time PCR analysis
Total RNA was isolated using TRIzol reagent according
to the manufacturer’s instructions (Promega Corporation,
Madison, WI, USA). RNA samples (2 μg) were reverse
transcribed using random hexamer primers and M-MLV
reverse transcriptase (Promega Corporation, Madison, WI,
USA) and the cDNA used for real-time PCR, performed
on a StepOnePlus™ Real-Time PCR Detection System using
Power SYBRGreen Master Mix™ (Applied Biosystems
Inc. Foster, CA, USA) following the manufacturer’s proto-
col. The PCR amplification reaction mixture (25 μl) con-
tained 50 ng of cDNA, 12.5 μl of SYBR Green Supermix,
and 0.2 μM of the UCP2 or GAPDH-specific primer pair.
The optimal primer concentrations were determined in
preliminary experiments. The PCR primers were de-
signed using ABI designer software Primer Express ver-
sion 2.0 (Applied Biosystems Inc. Foster, CA, USA) and
their sequences were UCP2 (Genbank accession nos.
AB 010743.1) forward 5’-GAA AGG CTC TCC CAA
TG-3’ and UCP2 reverse 5’-GGA GGT CGT CTG TCA
TGA GG-3’ and GAPDH (Genbank accession nos.
NM_017008.4) forward 5’-GGC CTT CCG TGT TCC
TAC C CAG-3’ and GAPDH reverse 5’-CGG CAT GTC
AGA TCC ACA AC-3’. In order to confirm amplifica-
tion specificity, the PCR products from each primer pair
were subjected to melting curve analysis. The reaction
conditions were incubation at 50°C for 2 min and initial
denaturation at 95°C for 10 min, followed by 40 cycles
of denaturation at 95°C for 20 s and annealing at 60°C
for 1 min. After real-time PCR, the temperature was in-
creased from 60 to 95°C at a rate of 0.5°C per second to
construct a melting curve. A negative control without
cDNA was run in parallel with each assay. Each reaction
mixture was amplified in triplicate and the results calcu-
lated based on the ΔΔCt method [23]. The cycle thresh-
old (Ct) value for the UCP2 gene was corrected using
the mean Ct value for the GAPDH gene. Relative gene
expression was expressed as the fold change (2−ΔΔCt)
relative to expression in the untreated control.
Western blotting
Cells were harvested and total cell lysates prepared using
lysis buffer [20 mM Tris–HCl (pH 7.2), 2 mM EGTA,
5 mM EDTA, 500 μM sodium orthovanadate, 10 mM so-
dium fluoride, 1% Triton X-100, 0.1% SDS and proteaseinhibitor cocktail]. Protein concentrations were determined
using protein assay reagents (Bio-Rad, Hercules CA, USA).
Forty to sixty micrograms of protein lysate was analyzed by
SDS-polyacrylamide gel electrophoresis. After transfer of
the proteins from the gel to a nitrocellulose membrane
(Amersham Pharmacia Biotech, Freiburg, Germany), the
membranes were blocked for 1 h at room temperature in
phosphate-buffered saline (PBS) containing 0.05% Tween
20 (PBS-T) and 5% nonfat dry milk, then were incubated
with anti-UCP2 (Santa Cruz Bio. Inc., MA USA) or anti-
VDAC1(Abcam, London, UK) polyclonal antibodies,
followed by horseradish peroxidase-conjugated second-
ary antibodies (pharMingen, San Diego CA, USA). The
immunoreactive bands were visualized using an enhanced
chemiluminescence kit (Perkin-Elmer Life Sciences,
Boston, MA, USA) and analyzed by QUANTITY ONE




Molecular Probes, Eugene, OR, USA) was used to measure
intercellular ROS production. After treatment, 10 μM
H2DCF-DA was added to the culture medium for 30 min,
then the cells were trypsinized and resuspended in Hanks’
balanced salt solution (Gibco, Grand Island, NY, USA). The
fluorescence of the dichlorofluorescein formed from the
oxidation of H2DCF-DA by cellular oxidants was measured
using a FACScalibur flow cytometry (BD Bioscience, San
Jose, CA, USA) with an excitation wavelength of 488 nm
and an emission wavelength of 525 nm. Data were analyzed
using WinMDI 2.8 software. As a positive control, 100 μM
H2O2 was added to H9C2 cells 2 h before cell harvesting.
Mitochondrial membrane potential measurement
Energy released during the oxidation reactions in the mito-
chondrial respiratory chain is stored as a negative electro-
chemical gradient across the mitochondrial membrane, and
the mitochondrial membrane potential (Δψ) is referred to
as being polarized. A change in the Δψ occurs during apop-
tosis and necrosis (depolarization) and cell cycle arrest (hy-
perpolarization) [24]. The mitochondrial Δψ was measured
using a fluorescent cationic dye, JC-1 (5,5’,6,6’-tetrachloro-
1,1’,3,3’- -tetraethylbenzimidazolcarbocyanine iodide) pro-
vided in a commercial kit (MitoScreen™ Kit, BD Bioscience,
San Jose, CA, USA). After treatment, the H9C2 cells were
incubated with JC-1 working solution for 15 min at 37°C,
then were trypsinized and resuspended for analysis by
FACScalibur flow cytometry (BD Bioscience, San Jose, CA,
USA). Data were analyzed using WinMDI 2.8 software.
Statistical analysis
All data are expressed as the mean ± SD. The significance
of differences was determined by one-way ANOVA
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formed using SAS (version 6.011; SAS Institute Inc,
Cary, NC. USA). A p value <0.05 was considered statis-
tically significant.
Results
DOX decreases cell viability and UCP2 expression
H9C2 cell viability was significantly decreased after 24 h
treatment with 0.5 or 1 μM DOX (Figure 1A). To exam-
ine whether this DOX-induced cell cytotoxicity was as-
sociated with altered expression of UCP2, mRNA was
extracted from DOX-treated H9C2 cells and subjected
by reverse transcription and quantitative real-time PCR
analysis. As shown in Figure 1B, UCP2 mRNA expres-
sion was significantly decreased by treatment with 0.5 or
1 μM DOX. The trends for cell viability and UCP2 ex-
pression were similar, suggesting the two are related.
Fatty acid composition of the cell and mitochondria after
EPA or DHA treatment
In order to investigate whether EPA or DHA was protect-
ive against the DOX-induced decrease in UCP2 expressionFigure 1 Doxorubicin decreases cell viability and UCP2 mRNA levels i
or 1 μM doxorubicin (DOX) for 24 h, then (A) cell viability was measured b
transcription and quantitative real-time PCR, with GAPDH (glyceraldehyde-3
expressed relative to the control value and are the mean ± S.D. for three in
**: p <0.01 compared to the untreated control.in H9C2 cells, we first determined the concentrations of
EPA and DHA at which the mitochondria were saturated
with the respective fatty acid, then measured UCP2
mRNA levels at these concentrations. Different concentra-
tions of EPA or DHA were added to H9C2 cells for 24 h,
then the cells were harvested and separated into subcellu-
lar compartments, followed by fatty acid pattern analysis.
We found that the EPA or DHA content of the total cell
lysate increased as the concentration of EPA or DHA used
increased, whereas that in the mitochondria reached a
maximum using concentrations of 100 μM EPA or 50 μM
DHA (Additional file 1). Table 1 shows that addition of ei-
ther EPA or DHA resulted in an increase in n-3 PUFAs in
the fatty acid composition of the total cell lysate at the ex-
pense of a significant decrease in oleic acid (C18:1, n-9)
and arachidonic acid (C20:4, n-6), while, in the mitochon-
dria, in addition to the above decreases, there were signifi-
cant decreases in levels of palmitic acid (C16:0) and
stearic acid (C18:0). It is noticeable that the docosapentae-
noic acid (C22-5, n-3) content was increased in both the
cell lysate and mitochondria after EPA treatment, suggest-
ing that acetyl-CoA elongation of EPA occurs in H9C2n H9C2 cells. H9C2 cells were left untreated or were treated with 0.5
y the MTT method and (B) UCP2 expression was measured by reverse
-phosphate dehydrogenase) as the internal control. The results are
dependent experiments. *: p <0.05 compared to the untreated control;
Table 1 Mole percentage of fatty acids in H9C2 cell (total cell lysate or mitochondria) after 24 h treatment with
100 μM EPA or 50 μM DHA
Fatty acid Total Mitochondria
(Mol %) Control EPA DHA Control EPA DHA
C12:0 1.16 ± 0.43 1.55 ± 0.32 1.58 ± 0.24 1.25 ± 0.32 1.19 ± 0.25 1.76 ± 0.33
C14:0 0.60 ± 0.06 0.86 ± 0.06 1.05 ± 0.07 0.98 ± 0.02 0.83 ± 0.04 0.72 ± 0.05
C15:0 0.21 ± 0.06 0.22 ± 0.03 0.74 ± 0.32 0.74 ± 0.19 0.75 ± 0.28 0.86 ± 0.39
C16:0 15.22 ± 2.00 15.06 ± 1.98 15.89 ± 1.86 18.94 ± 1.89 15.32 ± 2.11* 15.56 ± 1.54*
C:16:1 t 5.23 ± 1.18 5.16 ± 0.98 3.83 ± 1.18 5.73 ± 1.18 5.63 ± 0.26 5.83 ± 0.98
C16:1 2.86 ± 0.98 1.22 ± 0.81 0.97 ± 0.81 2.65 ± 0.90 2.65 ± 0.60 3.45 ± 1.86
C17:0 1.19 ± 0.23 1.52 ± 0.31 1.99 ± 0.23 1.45 ± 0.32 1.58 ± 0.26 2.49 ± 0.23
C18:0 21.82 ± 3.72 20.15 ± 3.56 19.36 ± 3.92 22.76 ± 1.72 18.73 ± 2.25* 18.36 ± 3.72*
C18:1 14.50 ± 1.06 12.69 ± 1.04* 12.50 ± 1.06* 13.40 ± 1.86 9.04 ± 2.02* 10.95 ± 2.06*
C:18:1 n-7 6.24 ± 0.98 5.06 ± 0.86 5.24 ± 0.95 5.31 ± 0.99 5.78 ± 0.67 5.44 ± 1.80
C18:2 t n-6 2.35 ± 0.46 2.26 ± 0.46 2.35 ± 0.84 3.86 ± 0.86 3.35 ± 0.76 3.35 ± 0.46
C18:2 n-6 2.97 ± 0.43 2.65 ± 0.34 2.40 ± 0.43 2.28 ± 0.58 2.59 ± 0.37 2.40 ± 0.73
C18:3 n-3 0.27 ± 0.17 0.37 ± 0.25 1.26 ± 0.87 0.17 ± 0.04 0.65 ± 0.25 0.67 ± 0.27
C20:0 0.31 ± 0.32 0.56 ± 0.12 0.66 ± 0.32 0.12 ± 0.02 0.18 ± 0.04 0.65 ± 0.32
C20:1 0.37 ± 0.03 0.38 ± 0.04 0.15 ± 0.03 0.24 ± 0.01 0.22 ± 0.02 0.87 ± 0.43
C20:2 1.79 ± 0.31 1.49 ± 0.28 1.15 ± 0.35 1.12 ± 0.05 1.36 ± 0.04 1.15 ± 0.41
C21:0 0.61 ± 0.26 0.51 ± 0.08 0.51 ± 0.26 1.06 ± 0.02 1.52 ± 0.21 1.17 ± 0.06
C20:3 n-6 1.14 ± 0.26 0.97 ± 0.17 1.02 ± 0.21 0.85 ± 0.18 0.93 ± 0.20 0.54 ± 0.06
C20:4 n-6 8.56 ± 1.15 6.67 ± 1.05* 5.59 ± 1.25* 7.67 ± 1.15 5.04 ± 0.19* 4.89 ± 0.25*
C20:3 n-3 0.65 ± 0.15 1.22 ± 0.39 0.90 ± 0.21 0.84 ± 0.19 0.70 ± 0.16 1.44 ± 0.59
C20:5 n-3 0.94 ± 0.25 5.52 ± 1.13* 0.91 ± 0.13 0.72 ± 0.13 5.52 ± 1.23* 0.91 ± 0.13
C23:0 1.14 ± 0.36 0.77 ± 0.56 0.99 ± 0.24 0.32 ± 0.15 0.29 ± 0.12 0.54 ± 0.36
C24:0 0.91 ± 0.13 0.73 ± 0.13 0.84 ± 0.25 0.58 ± 0.15 0.42 ± 0.14 0.99 ± 0.43
C22:5 n-3 3.18 ± 0.88 5.99 ± 1.23* 3.60 ± 0.48 3.05 ± 0.98 10.22 ± 2.08* 3.45 ± 0.96
C22:6 n-3 3.45 ± 0.96 2.97 ± 0.99 13.54 ± 2.89* 3.90 ± 0.56 4.24 ± 0.36 10.65 ± 1.23*
C24:1 1.91 ± 0.12 1.70 ± 0.19 1.54 ± 0.23 0.41 ± 0.11 0.28 ± 0.13 0.51 ± 0.23
n-3/n-6 PUFA 0.56 ± 0.08 1.35 ± 0.14* 1.85 ± 0.19*△ 0.59 ± 0.09 1.71 ± 0.18* 1.35 ± 0.15*△
All data are the mean ± S. D. for three separate experiments. PUFA: polyunsaturated fatty acids. *:p <0.05 as compared to the corresponding control; △:p <0.05
compared to the corresponding EPA treatment.
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ratio in the mitochondrial fatty acid.
UCP2 mRNA levels were increased by treatment with
100 μM EPA or 50 μM DHA, the increase with EPA be-
ing greater (Figure 2).
Pretreatment with EPA or DHA inhibits the DOX-induced
decrease in UCP2 expression
To examine whether the DOX-induced decrease in
UCP2 mRNA levels could be inhibited by pretreatment
or cotreatment with EPA or DHA, H9C2 cells were ei-
ther pretreated for 24 h with 100 μM EPA or 50 μM
DHA followed by 1 μM DOX treatment for 24 h in the
continued presence of the fatty acid or were cotreated
with 1 μM DOX and either 100 μM EPA or 50 μM DHA
for 24 h, then UCP2 mRNA levels were measured. Asshown in Figure 3, EPA pretreatment prevented the DOX-
induced decrease in UCP2 mRNA expression and DHA
pretreatment before DOX treatment results in a large in-
crease in UCP2 mRNA levels, whereas cotreatment with
EPA or DHA and DOX had no significant effect compared
to treatment with DOX alone.
In order to examine the effect on UCP2 protein expres-
sion, H9C2 cells were left untreated or were pretreated for
24 h with 100 μM EPA or 50 μM DHA, then were incu-
bated with or without 1 μM DOX treatment for 24 h in
the continued presence of the fatty acid and proteins were
extracted for Western blotting. Figure 4 shows that, in ac-
cordance with the mRNA result (Figure 2), EPA treatment
significantly increased UCP2 protein expression as com-
pared to the control. As expected, DOX treatment mark-
edly decreased UCP2 protein expression and this effect
Figure 2 EPA or DHA increases UCP2 mRNA levels in H9C2 cells. H9C2 cells were left untreated or were treated with 100 μM EPA or 50 μM
DHA for 24 h, then UCP2 mRNA expression was measured by reverse transcription and quantitative real-time PCR, with GAPDH (glyceraldehyde-
3-phosphate dehydrogenase) as the internal control. The results are expressed relative to the untreated control value and are the mean ± S.D. for
three independent experiments. *: p <0.05 compared to the untreated control; **: p <0.005 compared to the untreated control.
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DHA. The large increase in UCP2 mRNA levels seen with
DHA pretreatment before DOX treatment (Figure 3) was
not reflected in the protein levels (Figure 4), suggesting a
less effective translocation of UCP2 protein to the mito-
chondrial membrane.
Pretreatment with EPA or DHA inhibits the DOX-induced
ROS production, mitochondrial membrane potential
change and cell death
Several studies have ascribed the cardiotoxicity of DOX
to the induction of ROS [3] and mitochondria collapseFigure 3 Pretreatment with EPA or DHA prevents the doxorubicin-ind
untreated or (ii) treated with 100 μM EPA or 50 μM DHA for 24 h, then trea
doxorubicin (DOX) in the absence or presence of 100 μM EPA or 50 μM DH
transcription and quantitative real-time PCR, with GAPDH (glyceraldehyde-3
expressed relative to the untreated control value and are the mean ± S.D. f
untreated control; ##, # # #: p <0.01 and p <0.001 compared to doxorubicin[8]. We therefore examined whether EPA or DHA pre-
treatment of cells subsequently treated with DOX had
an effect on ROS and/or the mitochondrial membrane
potential. Figure 5 shows that DOX treatment dramat-
ically increased ROS production and that, although
treatment with either EPA or DHA alone resulted in a
significant increase in ROS as compared to the un-
treated control, pretreatment with EPA or DHA re-
duced the DOX-induced increase. Figure 6A shows that
DOX treatment results in a large decrease in the mito-
chondrial membrane potential (Δψ) and that this effect
was reduced by pretreatment with EPA or DHA. Auced decrease in UCP2 mRNA levels. H9C2 cells were (i) left
ted with 1 μM doxorubicin for 24 h or (iii) treated with 1 μM
A for 24 h, then UCP2 mRNA levels were measured by reverse
-phosphate dehydrogenase) as the internal control. The results are
or three independent experiments. ***: p <0005 compared to the
treatment alone, respectively.
Figure 4 Pretreatment with EPA or DHA prevents the doxorubicin-induced decrease in UCP2 protein expression. H9C2 cells were left
untreated or were treated with 50 μM DHA or 100 μM EPA for 24 h, then were left untreated or wre treated with 1 μM doxorubicin (DOX) in the
continued presence of the fatty acid for 24 h. After treatment, the cells were harvested and proteins extracted for Western blotting using antibody
against UCP2 with ß-actin as the internal control. The bars are the quantitative density analysis expressed as the relative density compared to
that in the untreated control and are the mean ± S.D. for three separate experiments. **, ***: p <001 and p <0.005 compared to the untreated
control, respectively; #: p <0.05 compared to doxorubicin treatment.
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induced cell death was prevented by the pretreatment
with EPA or DHA (Figure 6B).
Discussion
In this study, we found that DOX decreased UCP2
mRNA and protein levels in H9C2 cells and that this
was related to cell viability. Pretreatment with 100 μM
EPA or 50 μM DHA for 24 h resulted in the maximal
concentration of EPA or DHA, respectively, in mito-
chondrial fatty acid composition and prevented theFigure 5 Pretreatment with EPA or DHA prevents doxorubicin-induce
treated as in Figure 4, then intracellular ROS levels were measured using H
mean ± S.D. for three separate experiments. *, ***: p <005 and p <0.005 co
P <0.01 compared to doxorubicin treatment, respectively.DOX-induced reduction in UCP2 expression. However,
this effect was not found with cotreatment with DOX
and either EPA or DHA. Although EPA or DHA pretreat-
ment alone increased ROS production, both effectively
inhibited subsequent DOX-induced ROS production
and significantly inhibited the DOX-induced collapse
in the mitochondrial membrane potential (Δψ). These
findings show that EPA or DHA pretreatment pre-
vented the reduction in UCP2 expression induced by
DOX that might contribute to the cardiomyocyte tox-
icity of DOX.d reactive oxygen species (ROS) production. H9C2 cells were
2DCF-DA dye and flow cytometry. The results are expressed as the
mpared to the untreated control, respectively; #, # #: p <0.05 and
Figure 6 Pretreatment with EPA or DHA prevents the doxorubicin-induced change in the mitochondrial membrane potential (Δψ) (A)
and cell viability (B). H9C2 cells were treated as in Figures 4 and 5, then the Δψ was measured using JC-1 dye and flow cytometry. The results
are expressed as the mean ± S.D. for three separate experiments. **, ***: p <0.01 and p <0005 compared to the untreated; #, ##: p <0.05 and
p <0.01 compared to doxorubicin treatment.
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the semiquinone form by the transfer of one electron. The
DOX semiquinone can subsequently transfer an electron
to the oxygen molecule (O2) to form the superoxide anion
radical (O2
−) [3]. There is evidence that DOX can generate
ROS by two distinct mechanisms as it enters the cell. The
first involves DOX forming a complex with iron (III) and
transferring one electron to the iron to generate an iron
(II)-DOX free radical complex, which can then reduce
oxygen and hydrogen to superoxide anion radical and hy-
droxyl radical [25]. The second involves DOX generating
ROS through redox cycling, which is catalyzed by a num-
ber of NAD(P)H oxidoreductases [3,26]. It is believed that,
at the subcellular level, mitochondria are the primary tar-
get of DOX-induced cardiotoxicity, since heart tissue is
rich in mitochondria. Previous study has indicated that
the accumulation of redox-active DOX in these organelles
[3,27] would enhance mitochondrial production of ROS,resulting in interference with mitochondrial respiratory
function. In accordance with these findings, this study
shows a marked increase in ROS production in H9C2 cells
treated with DOX for 24 h.
UCPs are members of the anion carrier protein family
located in the inner mitochondrial membrane [17] and
do not transport protons in the absence of specific acti-
vators, but do transport protons and increase the net
proton conductance of mitochondria in the presence of
specific activators [28-30], including ROS and reactive
alkenals, such as hydroxynonenal, which is produced by
peroxidation of membrane phospholipids [31]. In the
present study, we found that, although DOX induced a
marked increase in ROS in H9C2 cells, UCP2 levels were
not increased and were even lower than basal levels,
which did not lessen the oxidative stress and resulted in
mitochondrial depolarization, leading to cell death. In
contrast, pretreatment with EPA or DHA inhibited the
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http://www.jbiomedsci.com/content/21/1/101DOX-induced decrease in UCP2 expression. UCP2 medi-
ates mild uncoupling and thus mitigates ROS production.
It is still unclear why and how UCP2 expression is de-
creased dramatically by DOX; changes in the composition
of cardiolipin could be one of the possible mechanisms.
Cardiolipin, the major phospholipid in the mitochondrial
membrane, participates in several important processes in
mitochondria, including oxidative phosphorylation, apop-
tosis and the assembly and functioning of mitochondrial
membrane proteins [7]. Altering the membrane phospho-
lipid composition changes the normal mitochondrial func-
tions. A previous study showed that DOX interacted with
cardiolipin, modulated mitochondrial membrane lipid
composition, and therefore caused mitochondrial dys-
functions [7]. Similarly, n-3 PUFAs affect the composi-
tions of cardiolipin as well. Dietary supplementation of
n-3 PUFAs increases the level of DHA in the cardiolipin,
decreases mitochondrial depolarization and therefore in-
creases cell survival [11]. We found that pretreatment
with n-3 PUFAs prevented DOX-induced reduction in
UCP2 expression, however, simultaneous treatment with
n-3 PUFAs and DOX did not. Pretreatment with n-3
PUFAs increased their incorporation into the mitochon-
drial membrane and modulated cardiolipin composition
in advance, while in the simultaneous treatment, the n-3
PUFAs had less effect on mitochondrial composition due
to their competition with DOX in modulating lipid com-
position at the same time. Taken together, we propose that
the protective effect of n-3 PUFAs might be due to the in-
corporation of n-3 PUFAs into cell membrane phospho-
lipids and cardiolipin [10,11] rather than to a direct effect
on UCP2, thus altering membrane fluidity, modulating cell
signaling [32], and enhancing free radical production [33].
Further experiments are needed to explore the transcrip-
tional events and target genes related to UCPs that are af-
fected by DOX and n-3 PUFAs.
N-3 PUFAs have diverse effects on cardiomyocytes and
cancer cells. In cardiomyocytes, n-3 PUFAs protect cells
from cardiac injury via multiple molecular mechanisms
including anti-inflammation, altering the membrane
composition and fluidity, regulating gene expression,
converting to bioactive metabolites and maintaining mito-
chondrial functions [10,11]. As anti-cancer agent, in con-
trast, n-3 PUFAs are associated with the properties of
anti-inflammation, anti-proliferation, proapoptosis, anti-
metasis, anti-invasion, and anti-angiogenesis [14]. It is evi-
dent that n-3 PUFAs induce apoptosis in cancer cells by
triggering excessive ROS production and inducing au-
tophagy [34,35]. Having more unsaturated double bonds
and bis-allylic hydrogens than monounsaturated fatty acid,
n-3 PUFAs are much more prone to spontaneous oxida-
tion and result in an increase in ROS production [36].
Compared to normal cells, cancer cells have higher levels
of mitochondrial ROS generation for cellular proliferationand tumorigenesis, the ROS products further attack n-3
PUFAs and cause more lipid peroxidation and lead to
apoptosis in cancer cells [14]. In normal cells, lipid perox-
ides are the major ROS products generated by n-3 PUFAs
[37-39], whereas neither oxidatively modified protein nor
oxidized LDL is induced by n-3 PUFA supplementation
[39,40]. In addition, accumulating evidences show that
oxidative modification of n-3 PUFAs is biologically active
and benefits the cardiac functions [41-43]. Consequently,
although our data show a small but statistically significant
increase in ROS production induced by n-3 PUFAs, the
clinical relevance of this change is questionable. It is
evident that n-3 PUFA pretreatment reduces DOX-
induced ROS production. However, the present data
could not clarify whether n-3 PUFA reduces ROS gener-
ation via UCP2 or not. UCP2 overexpression and a short
interfering RNA system are required to further elucidate
the related mechanism.
It has been reported that the amount of DOX-induced
ROS production is positively correlated with the mem-
brane unsaturation index of fatty acids; these lipid per-
oxides have been implicated in the cytotoxic process and
the increase in drug efficacy in cancer cells [20,44,45].
Our results showed that pretreatment with EPA or DHA
substantially increased the unsaturation index of mito-
chondria and enhanced ROS production in H9C2 cells
in the absence of DOX. However, when the cells were
treated with DOX, ROS production was not significantly
changed in the EPA or DHA pretreated group, but was
markedly increased in the non-pretreated group. Ac-
cordingly, we propose that myocytes and cancer cells
may have different mechanisms for responding to DOX-
induced toxicity, and whether UCP expression is upreg-
ulated or not may determine whether n-3 PUFAs cause
an improvement or worsening of DOX-induced oxida-
tive stress.Conclusion
EPA or DHA pre-treatment inhibits the DOX-induced de-
crease in UCP2 expression, increase in ROS production,
and subsequent mitochondrial membrane potential change
that contribute to the cardiotoxicity of DOX. This study
highlights the possibility that pretreatment with n-3 PUFAs
might be useful in reducing DOX-induced oxidative stress
in cardiomyocytes, and provides clues for studying the role
of UCPs in this mechanism. However, the present cell
model did not provide solid evidences to verify all the
protective mechanisms of n-3 PUFA on DOX-induced
cytotoxicity. In the future, conducting a gain-of-function/
loss-of-function assay, especially via a transgenic animal
model, would be preferable for obtaining information on
gene function and regulation by n-3 PUFAs as well as on
DOX-induced cardiomyocyte cytotoxicity.
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